The method of introduction of a preparation containing recombinant2- interferon

 

(57) Abstract:

The invention relates to medicine, namely to physiotherapy. Inhalation enter product containing recombinant2-interferon, before its introduction use any physiotherapeutic procedure liquefy the sputum and/or improving its passage. This method increases the bioavailability of the drug in the upper and lower respiratory tract by increasing the relative concentration and exposure in the respiratory tract. 1 C.p. f-crystals.

The invention relates to medicine, namely to physiotherapy, and can be used for the treatment of acute respiratory diseases, complicated by tracheitis, bronchitis.

Known methods of inhalation reference preparations of recombinant2-interferon for prevention and treatment of acute respiratory diseases [1, 2]. Preparations of recombinant interferon is administered by inhalation ME 25 thousand to 1 inhalation once daily for 5 days [1] or 2 times per day on 100 thousand IU/kg of body weight of children of the first year and 50 thousand IU/kg of body weight over one year of age [2]. Additionally injected vitamin E and ascorbic acid.

The main disadvantage of the known methods of inhalation weekto is to reduce the bioavailability of recombinant2-interferon in violation of its diffusion, reducing the relative concentration and exposure in the respiratory tract due to hypersecretion of mucus, is able to inactivate interferon, edema, disorders of mucociliary clearance, especially if there are evident signs of inflammation.

The inventive method of treatment of acute respiratory diseases by inhalation products containing recombinant interferon, which are new and are not described in literature.

The technical result is the potentiation when using physiotherapy treatments, thinning sputum and/or improving its passage, the actions of inhalation of recombinant2-interferon, increasing its bioavailability in the upper and lower respiratory tract by increasing the relative concentration and exposure in the respiratory tract, including the combination of recombinant 2-interferons with immunoglobulins.

According to the invention use before inhalation drug containing recombinant 2-interferon, any physiotherapy treatments, thinning sputum and/or improving its passage, provides the mixture of recombinant interferon and immunoglobulin.

The proposed method interferonoterapii tested in children with frequent episodes of acute respiratory infections.

Embodiments of the invention

Example 1. Patient R., aged 6. Diagnosis: the Louis-Bar syndrome, acute respiratory infections. History of frequent colds, proceeding with acute exacerbations of chronic bronchitis in the next 3-4 months. After the treatment there was a slight clinical improvement. Continued coughing with detachable hard sputum, low grade fever, lung auscultation abundance occasional wheeze. A course of treatment consisting of 5 treatments using oscillatory stimulation of the respiratory tract, thinning phlegm and improve its passage, followed by the inhalation of the drug containing recombinant2-interferon and immunoglobulin. To the end of treatment, the child's condition has improved considerably. He stopped fever. Cough much less softer. When observed in the dynamics of the child closer to satisfactory. Once observed ARD without the expressed exacerbation of chronic bronchitis, which is treated without antibiotics.

Example 2. Patient K., aged 15. The child was noted frequent colds, flowing the research Institute of the child were used physiotherapy in the form of massage, improving passage sputum, followed by inhalation of recombinant2-interferon. Conducted 5 sessions. When observed in the dynamics after treatment repeated episodes of acute respiratory infections have been noted.

Example 3. The patient Was 2 years. The child of a group of sickly respiratory diseases of children. Diagnosed with recurrent bronchitis. Exacerbation was observed monthly and proceeded with severe obstructive syndrome. In the treatment of frequently used antibiotics. When it arrives at the treatment of the child's condition is moderate. Marked moderately expressed signs of intoxication syndrome of bronchial obstruction. In treatment were used physiotherapy, including massage, electrophoresis with calcium chloride or oscillatory stimulation of the respiratory tract followed by the inhalation of the drug containing recombinant2-interferon and immunoglobulin. In the treatment of the child's condition has improved. There has been a rapid clinical dynamics. Over the next 3 months was observed only once episode ARD without deploying bronchoobstructive syndrome with rapid clinical improvement.

Thus, ofizioterapia procedures thinning sputum and/or improving its passage, provides high efficiency interferonoterapii, reduces the duration of treatment.

Sources of information

1. RF patent N 2097062, class A 61 K 38/21, 1993.

2. He M,, Malashkin A. B., Bratina, S., Anikin Century b2-2-interferon in treatment of respiratory allergic. // Methodological basis for the application of reaferona - human recombinant interferon-2 protein. The collection of materials of scientific conference for practitioners. Koltsovo, 25-29 January 1993 - Koltsovo, 1993. - S. 78-80.

1. A method of treating acute respiratory diseases by inhalation of the drug containing recombinant2-interferon, characterized in that prior to inhalation drug containing recombinant2-interferon, use any physiotherapeutic procedure liquefy the sputum and/or improving its passage.

2. The method according to p. 1, characterized in that simultaneously with the preparation containing recombinant2-interferon, inhalation administered immunoglobulins.

 

Same patents:

The invention relates to the field of biochemical pharmacology and medicinal chemistry

The invention relates to new derivatives naphthiridine formula I, where R1denotes phenyl, benzyl, 3-nitrophenyl, 3-chlorophenyl, 3-tianfeng, 3-(tetrazolyl)phenyl or benzofuranyl; R2denotes a hydroxy-group, tripterocalyx, allyl, alkyl, alkenyl, quinil, alkoxygroup, phenyl, phenyloxy, carboxyphenyl, carboxymethyl, carbamoylmethyl, phenylamino, diphenylamino-, amino-, elcamino, Alcaidaria, where "ALK" refers to aliphatic fragment having up to 8 carbon atoms and optionally including carboxylate, ether carboxylic acid or a hydroxy-group and/or optionally containing ether and/or ester bond, or its N-oxide in free form or in the form of a pharmaceutically acceptable salt

The invention relates to medicine, namely to the combined drug, possess expectorant, anti-inflammatory and antiallergic effect, and can be used in complex therapy of inflammatory diseases of the Airways and lungs

The invention relates to new ascomycin General formula I, where Y represents a phenylene; Z is selected from carboxyl and physiologically hydrolyzable of oxycarbonyl or alkyl, CNS, alkylamino or dialkylamino bearing from 1 to 4 carboxyl or physiologically hydrolyzable oxycarbonyl group; Q is O or S; R1Is H, alkyl or aryl; R2is hydrogen or hydroxyl; R3is methyl, ethyl, propyl or allyl; R4is hydroxyl or alkoxyl; R5-oxoprop or (H, OH), R6- oxoprop, H, HE H, alkoxyl); n is an integer 1 or 2, in free form or in the form of a pharmaceutically acceptable salt

The invention relates to medicine, namely to clinical phototherapy, and can be used for treatment of bronchial asthma

The invention relates to new derivatives of benzothiazolone General formula I where X is-SO2NH - or-NНSО2-; p, q and r independently of one another represent 2 or 3; Y represents thienyl, optionally substituted C1-6by alkyl or halogen, or phenylthio or phenyl, optionally substituted C1-6by alkyl or halogen; each R independently represents H or C1-6alkyl; its optical isomers and pharmaceutically acceptable salts

The invention relates to new derivatives of benzothiazolone General formula I where X is-SO2NH - or-NНSО2-; p, q and r independently of one another represent 2 or 3; Y represents thienyl, optionally substituted C1-6by alkyl or halogen, or phenylthio or phenyl, optionally substituted C1-6by alkyl or halogen; each R independently represents H or C1-6alkyl; its optical isomers and pharmaceutically acceptable salts
The invention relates to medicine and can be used in complex treatment of patients with pneumonia

The invention relates to medicine, namely to physiotherapy, and can be used for the treatment of respiratory diseases, including bronchial asthma, asthmatic bronchitis, allergic diseases of the upper respiratory tract, rhinitis, etc., and also for treatment of skin with the use of the sauna

The invention relates to medical equipment, inhalation devices and methods of inhalation

Respiratory trainer // 2165269
The invention relates to a means for learning methods for treating respiratory, allows you to extend the parametric functionality of the respiratory simulator and to ensure the safety of the training process in a wide range of options

Dispenser-dispenser // 2163819
The invention relates to medicine

The invention relates to medical engineering, in particular to devices for administering drugs to the lungs of a patient, and more particularly to a device for inhalation of the medicinal powder which is a mixture of fine particles of the active component and the coarse particles of the powder carrier

The invention relates to medicine

The invention relates to medicine, in particular to the prevention and treatment of alcoholism, nicotinamine and addiction in General
The invention relates to medicine, in particular to urology, and can be used for the treatment of benign prostatic hyperplasia
Up!